GSK Blenrep combinations approved by UK MHRA in relapsed/refractory multiple myeloma Ruchika Sharma20 April 2025 10:00 AM ISTGSK plc has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has authorised Blenrep. In the UK, Blenrep is...
JnJ gets European Commission nod for subcutaneous Darzalex-based quadruplet regimen for newly diagnosed multiple myeloma Ruchika Sharma11 April 2025 10:30 AM ISTBelgium: Janssen-Cilag International NV, a Johnson & Johnson company, has received approval from the European Commission (EC) for an...
Shilpa Medicare marketing partner Amneal Pharma unveils multiple myeloma treatment Boruzu Ruchika Sharma4 April 2025 12:30 PM ISTKarnataka: Shilpa Medicare has announced that the Company's marketing partner, Amneal Pharmaceuticals, has launched BORUZU, (Bortezomib...
Sanofi Sarclisa combo gets Japanese nod for newly diagnosed multiple myeloma Ruchika Sharma27 Feb 2025 11:30 AM ISTParis: Sanofi has announced that the Ministry of Health, Labour and Welfare (MHLW) in Japan has approved Sarclisa, in combination with...
Sanofi Sarclisa approved in China for patients with newly diagnosed multiple myeloma ineligible for transplant Ruchika Sharma2 Feb 2025 10:45 AM ISTParis: Sanofi has announced that the National Medical Products Administration (NMPA) in China has approved Sarclisa, in combination with a...
Sanofi Sarclisa approved in EU for newly diagnosed multiple myeloma Ruchika Sharma26 Jan 2025 1:30 PM ISTParis: Following the adoption of a positive opinion by the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use...
Blenrep combo accepted for priority review in China in relapsed/refractory multiple myeloma: GSK Ruchika Sharma11 Dec 2024 1:30 PM ISTLondon: GSK plc has announced that the National Medical Products Administration (NMPA) of China has accepted for review a new drug application...
USFDA accepts for review application for GSK Blenrep combinations for multiple myeloma treatment Ruchika Sharma26 Nov 2024 5:52 PM ISTLondon: GSK plc has announced the US Food and Drug Administration (FDA) has accepted for review a Biologics License Application (BLA) for...
Sarclisa recommended for EU approval by CHMP to treat transplant-ineligible newly diagnosed multiple myeloma: Sanofi Ruchika Sharma17 Nov 2024 4:00 PM ISTParis: Sanofi has announced that the European Medicines Agency (EMA)'s Committee for Medicinal Products for Human Use (CHMP) has adopted a...
JnJ seeks USFDA nod for Darzalex Faspro-based quadruplet regimen for newly diagnosed multiple myeloma patients for whom transplant is not planned Ruchika Sharma6 Oct 2024 10:30 AM ISTRaritan: Johnson & Johnson has announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug...
Darzalex-based quadruplet regimen receives positive CHMP opinion for transplant-eligible patients with newly diagnosed multiple myeloma Ruchika Sharma22 Sept 2024 12:30 PM ISTBeerse: Janssen-Cilag International NV, a Johnson & Johnson company, has announced that the Committee for Medicinal Products for Human Use...
USFDA nod to Sanofi Sarclisa in combo with bortezomib, lenalidomide, dexamethasone for newly diagnosed multiple myeloma not eligible for transpant Ruchika Sharma21 Sept 2024 2:25 PM ISTParis: Sanofi has announced that the US Food and Drug Administration (FDA) has approved Sarclisa (isatuximab) in combination with bortezomib,...
